Novo Nordisk to spend more on acquisitions and external innovation

The success of its GLP-1 molecule in recent years has led Novo Nordisk to increase its focus on acquisitions and external drug candidates and companies.

Photo: Novo Nordisk / PR

Novo Nordisk's successful GLP-1 drug is creating new opportunities for the Danish pharmaceutical giant, which has stated it can no longer rely exclusively on drugs developed in-house, Danish financial daily Børsen reports.

In an interview with Endpoints News, CEO Lars Fruergaard Jørgensen says that Novo Nordisk will continue to make investments over the next year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs